PCSK9 Forum
Click here to invite colleagues
to join the Forum for FREE
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
From the Editors

PCSK9 inhibitors in acute coronary syndromes

Baris Gencer, Geneva University Hospitals, Switzerland, discusses evidence for PCSK9 inhibition in acute coronary syndromes.

Read the report »
Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?

New and updated edition of our popular therapeutic guide

A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

As you know, this downloadable e-book is freely available to all registered members of the Forum.

Read online » Download now »

Forward to colleagues »
  New eBook
Click here to invite colleagues to join FREE
Questions & Answers
Why are new treatments needed?
Inhibition of PCSK9 offers the real possibility of improved management of high-risk patients.

Read the full answer and other questions on the PCSK9 Forum »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.